Who will receive the new mpox antiviral drug and vaccine first?

Question

Accepted Answer

High-Risk Individuals to Receive Priority for Mpox Antiviral Drug and Vaccine

The first shipment of the mpox antiviral drug Tecovirimat has arrived in Malaysia and will be reserved for high-risk individuals. Similarly, an agreement for an mpox vaccine has been finalised, with its delivery expected soon, and it will also be prioritised for high-risk groups.
Mpox Antiviral Drug Allocation

The newly arrived Tecovirimat medication is designated for high-risk individuals. This category specifically includes those suffering from severe diseases or possessing weakened immune systems, ensuring that critical cases receive the initial supply of the antiviral treatment.
Mpox Vaccine Prioritisation

Malaysia has finalised an agreement for an mpox vaccine, with its arrival anticipated shortly. Similar to the antiviral drug, the vaccine will be prioritised for high-risk groups within the population, reflecting a targeted approach to managing potential outbreaks.
Ongoing Mpox Surveillance

While specific treatments and preventative measures are being rolled out, monitoring for mpox cases continues. The most recent case was detected on September 16, involving a patient who tested positive for the Clade 2 sub-variant and has since been isolated and is in stable condition. Close contacts of this individual have been identified and are under health observation.

Reading history

Hide →

This history is cleared when the page is closed.

Who will receive the new mpox antiviral drug and vaccine first?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends